论文部分内容阅读
头孢洛扎/他唑巴坦为复方制剂,组分为头孢洛扎和他唑巴坦(标示量之比为2∶1),对铜绿假单胞菌具有极强的抗菌活性,对产超广谱β-内酰胺酶的肠杆菌属也有良好的抗菌活性。2014年12月,经FDA批准,可用于成人患者治疗由敏感的革兰阴性菌导致的复杂性尿路感染和复杂性腹腔内感染。本文从头孢洛扎/他唑巴坦的化学结构、作用机制、体外抗菌活性与耐药、药代动力学与药效学、临床应用、安全性等方面对其作述评。
Cefluloraxan / tazobactam is a compound preparation, the composition of cefaclor and tazobactam (labeled amount ratio of 2: 1), has strong antibacterial activity against Pseudomonas aeruginosa, the production of super Enterobacter sp. Broad-spectrum β-lactamase also has good antibacterial activity. December 2014, approved by the FDA for use in adult patients for the treatment of complicated urinary tract infections and complicated intraperitoneal infections caused by sensitive Gram-negative bacteria. This article reviews the chemical structure, mechanism of action, in vitro antibacterial activity and drug resistance, pharmacokinetics and pharmacodynamics, clinical application, safety and so on of ceflulosavir / tazobactam.